US Pharma MarketingMerck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
Merck KGaA agrees to buy Silence Therapeutics for $1.3B, adding siRNA drug divesiran, which is headed to Phase 3 in polycythemia vera. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Germany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic medicines.
Silence is developing the siRNA drug divesiran, which is ...
Source: Endpoints News